Global biopharmaceutical company
Awareness of the need for access to all FDA-approved medications for treatment of substance use disorder Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder Initiatives to promote the use of relapse prevention post detoxification Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings in FY23 appropriations for Labor-HHS and CJS bills -- H.R. 2617, Consolidated Appropriations Act, 2023 Maintain access to mental health medications for the low-income subsidy (LIS) eligible population under Medicare Part D in prescription drug reform legislation -- H.R.5376 - Inflation Reduction Act implementation issues
HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 1 - SENATE
SPLITOAK STRATEGIES LLC
300 New Jersey Avenue, NW, Suite 900, Washington, DC, 20001, US
SARAH KUEHL EGGE SARAH KUEHL EGGE